Dublin, Aug. 15, 2017 (GLOBE NEWSWIRE) -- The "Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030" report has been added to Research and Markets' offering.
The Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030' report provides an extensive study on liquid biopsy kits/assays that are either commercialized or are under development for diagnosis and/or monitoring of different types of cancer.
The market is characterized by the presence of several companies that have proprietary technologies/platforms for either isolation/enrichment/enumeration of CTCs or for molecular characterization/sequencing of the genetic material extracted from the CTCs/exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, and patient and recurrence monitoring of different cancer indications. Such kits are likely to transform the cancer diagnostics market with many commercial success stories in the near future.
The market is primarily led by start-ups/small companies, such as (in alphabetical order) CellMax Life, Celsee Diagnostics, Datar Genetics, DiaDx, EONE-DIAGNOSTICS Genome Center, Exosome Sciences, iCellate Medical, Inivata, IVDiagnostics, LCM Genect and MDNA Life Sciences. It also has presence of mid to large-sized pharma players; notable examples include (in alphabetical order) Biocartis, Counsyl, Foundation Medicine, Genomic Health and NeoGenomics Laboratories.
In addition to the aforementioned players, a number of pharma giants are also developing assets in this field. Prominent players under this category include (in alphabetical order) Affymetrix, Menarini Silicon Biosystems, Myriad Genetics, QIAGEN, Roche, Siemens Healthineers and Thermo Fisher Scientific.
As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives of this report was to understand the future potential of the market.
In addition, we have provided a comprehensive market estimation to determine the global evolution of the liquid biopsy market. This has been done by evaluating the likely success of key applications of early diagnosis, recurrence monitoring and patient monitoring. We have included insights on the likely regional evolution of the market covering US, EU5 and rest of the world. In addition, we have estimated the likely contribution of different target patient populations to the global market; this covered key indications including (in alphabetical order) bladder cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer.
Further, we segmented the market by the type of markers (CTCs, ctNAs, exosomes) and the sample source (blood, urine, saliva) used in different liquid biopsies. In order to account for uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios for the time period 2017-2030. The conservative, base and optimistic scenarios represent three different tracks of the industry's evolution. The research, analysis and insights presented in this report are backed by the deep understanding of key insights gathered from both secondary and primary research.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease
3.3. Importance of Early Detection in Cancer
3.4. Detecting Cancer: Screening vs. Diagnosis
3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.1.1. Fine Needle Aspiration Biopsy
3.5.1.2. Core Needle Biopsy
3.5.1.3. Vacuum-Assisted Biopsy
3.5.1.4. Image-Guided Biopsy
3.5.1.5. Sentinel Node Biopsy
3.5.1.6. Surgical Biopsy
3.5.1.7. Endoscopic Biopsy
3.5.1.8. Bone Marrow Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Approaches
3.7. Costs and Benefits Associated with Non-Invasive Tests
4. CONCEPT OF NON-INVASIVE CANCER SCREENING AND DIAGNOSTICS
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerized Tomography (CT) Scan
4.2.5. Integrated PET-CT Scan
4.2.6. Ultrasound
4.2.7. Barium Enema
4.3. Screening Assays
4.3.1. Papanicolaou Test (Pap Test) and Human Papilloma Virus Test (HPV Test)
4.3.2. Tumor Marker Test
4.3.3. Fecal Occult Blood Tests (FOBT)
4.3.4. Digital Rectal Exam (DRE)
4.3.5. Multigated Acquisition (MUGA) Scan
4.4. Advanced Non-Invasive Approaches
4.4.1. Liquid Biopsy
4.4.2. Cytogenetic/Gene Expression Studies
4.4.3. Molecular Signature Based Non-Invasive Methods
4.4.4. Saliva-Based Oral Cancer Diagnostics
4.4.5. Vital Staining
4.4.6. Optical Biopsy
4.4.7. Other Techniques
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Liquid Biopsy: Development Landscape
5.2.1. Liquid Biopsy Tests: Distribution by Development Stage
5.2.2. Liquid Biopsy Tests: Distribution by Sample Type
5.2.3. Liquid Biopsy Tests: Distribution by Type of Markers Detected
5.2.4. Liquid Biopsy Tests: Distribution by Indication
5.2.5. Liquid Biopsy Tests: Distribution by Type of Application
5.2.6. Liquid Biopsy Tests: Distribution by Geographical Coverage
5.2.7. Liquid Biopsy Tests: Distribution by Leading Players
5.3. Liquid Biopsy: Technologies, Platforms, Systems and Instruments
6. LIQUID BIOPSY MARKET: KEY INSIGHTS
6.1. Chapter Overview
6.2. Liquid Biopsy Tests: Competitive Landscape of Developers
6.3. Liquid Biopsy Tests: Distribution by Application and Target Indications
6.4. Emerging Trends on Non-Invasive Cancer Diagnostics on Social Media
6.4.1. Non-Invasive Cancer Diagnostics: Historical Trends by Twitter Volume (2010-2016)
6.4.2. Non-Invasive Cancer Diagnostics: Twitter Word Cloud (2010, 2012, 2014, 2016)
6.4.3. Non-Invasive Cancer Diagnostics: Twitter Trends for Popular Indications (2010-2016)
6.4.4. Non-Invasive Cancer Diagnostics: Twitter Trends for Samples Types (2010-2016)
7. LIQUID BIOPSY: DETAILED OUTLOOK
7.1. Chapter Overview
7.2. Non-Invasive Methods Over Biopsies for Detection of Cancer
7.3. Circulating Biomarkers for Cancer
7.3.1. Circulating Tumor Cells (CTCs)
7.3.1.1. Advantages Associated with the Use of CTCs
7.3.1.2. Challenges Associated with the Use of CTCs
7.3.2. Circulating Tumor DNA (ctDNA)
7.3.3. Exosomes
7.4. Liquid Biopsy Based Tests and Systems
7.4.1. BioFluidica CTC Isolation Technology, CTC Analysis System and Test, BioFluidica/Roche
7.4.2. CancerIntercept Detect and CancerIntercept Monitor, Pathway Genomics
7.4.3. Cancertrack, Datar Genetics
7.4.4. CellMax-LBx Liquid Biopsy and CellMax-CRC Colorectal Cancer Blood Test, CellMax Life
7.4.5. CELLSEARCH System and CELLSEARCH CTC Test, Menarini Silicon Biosystems
7.4.6. cobas EGFR Mutation Test v2, Roche
7.4.7. LiquidBiopsy Rare Cell Isolation Platform, ClearID Total Insight Breast Cancer, ClearID Lung Cancer and Clear ID Melanoma, Cynvenio Biosystems
7.4.8. Oncocount, Oncotrace, Oncotrial and Metastat, R.G.C.C. Group
7.4.9. OncoBEAM CRC RAS Kit, Sysmex Inostics/Merck
7.4.10. OnTarget Assay, Boreal Genomics
7.4.11. PrediSeq-Prostate and PrediSeq-Lung, Predicine
7.4.12. SelectMDx, MDxHealth
7.4.13. ViewRNA CTC Platform and Assay, Affymetrix
7.4.14. Velox, IVDiagnostics
7.4.15. ApoStream System and Technology, ApoCell
7.4.16. IsoPic, iCellate Medical
7.4.17. Parsortix System, ANGLE
7.5. Companion Liquid Biopsies: Recent Developments
7.5.1. Biocept and Baylor College of Medicine
7.5.2. Tokai Pharmaceuticals and QIAGEN
7.5.3. ANGLE and MD Anderson Cancer Center
7.5.4. AstraZeneca and QIAGEN
7.5.5. Sysmex Inostics and Bayer Healthcare
8. VENTURE CAPITAL FUNDING
8.1. Chapter Overview
8.2. Types of Funding
8.3. Liquid Biopsy Market: Funding Instances, 2011-2017
8.4. Liquid Biopsy Market: Distribution by Year
8.5. Liquid Biopsy Market: Distribution of Type of Model
8.6. Leading Players: Distribution by Funding Instances
9. COMPANY VALUATION ANALYSIS
9.1. Chapter Overview
9.2. Company Valuation: Methodology
9.3. Company Valuation: Categorization by Multiple Parameters
9.3.1. Categorization by Google Hits Score
9.3.2. Categorization by Awards Score
9.3.3. Categorization by Twitter Score
9.3.4. Categorization by Twitter Followers Score
9.3.5. Categorization by Number of Products
9.3.6. Categorization by Uniqueness Score
9.3.7. Categorization by Weighted Average Score
10. LIQUID BIOPSY: KEY PLAYERS
10.1. Chapter Overview
10.2. Biocartis
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Portfolio
10.2.3.1. Idylla ctBRAF Mutation Assay (RUO)
10.2.3.2. Idylla ctKRAS Mutation Assay
10.2.3.3. Idylla ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO)
10.3. Biocept
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Portfolio
10.3.3.1. Target Selector Breast Cancer Test
10.3.3.2. Target Selector Lung Cancer Test
10.3.3.3. Target Selector Immuno-Oncology PD-L1 Test
10.3.3.4. Target Selector Gastric Cancer Test
10.3.3.5. Target Selector Colorectal Cancer Test
10.3.3.6. Target Selector Prostate Cancer Test
10.3.3.7. Target Selector Melanoma Test
10.4. Biodesix
10.4.1. Company Overview
10.4.2. Financial Information
10.4.3. Product Portfolio
10.4.3.1. GeneStrat
10.4.3.2. VeriStrat
10.5. Exosome Diagnostics
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Product Portfolio
10.5.3.1. ExoDx Prostate (IntelliScore)
10.5.3.2. ExoDx Lung (ALK)
10.5.3.3. ExoDx Lung (EGFR/T790M)
10.5.3.4. ExoDx Solid Tumor
10.6. Genomic Health
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Portfolio
10.6.3.1. Oncotype SEQ Liquid Select
10.7. Guardant Health
10.7.1. Company Overview
10.7.2. Financial Information
10.7.3. Product Portfolio
10.7.3.1. Guardant360
10.8. NeoGenomics Laboratories
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Portfolio
10.8.3.1. NeoLAB HEME
10.8.3.2. NeoLAB Solid Tumor Monitor (NeoLAB SOLID TUMOR)
10.8.3.3. NeoLAB Prostate
10.8.3.4. NeoLAB EGFR T790M Liquid Biopsy
10.9. Personal Genome Diagnostics (PGDx)
10.9.1. Company Overview
10.9.2. Financial Information
10.9.3. Product Portfolio
10.9.3.1. MetDETECT
10.9.3.2. PlasmaSELECT R 64
10.9.3.3. LungSELECT
10.10. QIAGEN
10.11. Transgenomic
10.12. Trovagene
11. OTHER NON-INVASIVE CANCER DIAGNOSTICS
11.1. Chapter Overview
11.2. Non-Blood Based Biomarker Detection Tests
11.3. DNA Methylation Detection Tests
11.4. Fecal Occult Blood Test (FOBT) AND Fecal Immunochemical Test (FIT)
11.5. MicroRNA (miRNA) Based Test
11.6. Pigmented Lesion Assay
11.7. Stool DNA (sDNA) Testing
11.8. Volatile Organic Compound (VOC) Detection Test
11.9. Other Non-Invasive Cancer Diagnostics: Market Landscape
11.10. Other Non-Invasive Cancer Diagnostics: Survey Analysis
11.10.1. Survey Analysis: Seniority Level of Respondents
11.10.2. Survey Analysis: Type of Product Portfolio
11.10.3. Survey Analysis: Types of Products/Services Offered
11.10.4. Survey Analysis: Type of Application
11.10.5. Survey Analysis: Availability of the Products
11.10.6. Survey Analysis: Likely Market Size
12. MARKET SIZING AND FORECAST
12.1. Chapter Overview
12.2. Forecast Assumptions and Methodology
12.3. Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030
12.3.1. Liquid Biopsy Market Forecast, 2017-2030
12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030
13. CONCLUSION
13.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care in the Field of Oncology
13.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer Management
13.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis
13.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range of Applications
13.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different Geographies
13.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further Strengthen the Ongoing Innovation
13.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential
13.8. Primarily Led by Liquid Biopsy, The Non-Invasive Cancer Diagnostics Market has Emerged as a Multi-Billion Dollar Market
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Burkhard Jansen, MD, Chief Medical Officer, DermTech
14.3. Frank Szczepanski, President and CEO, IVDiagnostics
14.4. Riccardo Razzini, Sales and Marketing Manager, LCM Genect
14.5. Nathalie Bernard, Marketing Director, OncoDNA
14.6. Abizar Lakdawalla, Founder, ProXeom
14.7. Mark Li, CEO, Resolution Bioscience
14.8. Christer Ericsson, Chief Scientific Officer, iCellate Medical
14.9. Philippe Nore, CEO and Co-founder, MiNDERA
14.10. Jake Micallef, Chief Scientific Officer, VolitionRx
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/research/sdm2rg/noninvasive